|
Rituximab Doesn’t Alleviate Sjögren Symptoms at Week 24
Doctors Lounge FRIDAY, Feb. 21, 2014 (HealthDay News) — For patients with primary Sjögren syndrome (pSS), rituximab does not improve symptoms or disease activity at 24 weeks, according to a study published in the Feb. 18 issue of the Annals of Internal Medicine. |
|
Funding restrictions for rituximab and eltrombopag widened in New Zealand
The Pharma Letter New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen the restriction on rituximab use in DHB hospitals and expand the funding of eltrombopag in both hospitals and the community. This was the … |
|
Rituximab Disappoints in Sjögren Syndrome
Medscape The investigators observed no significant differences at 24 weeks between groups receiving rituximab or placebo in any clinical endpoints or symptoms, including pain, fatigue, salivary flow, and tear production. The drug was administered in 2 infusions … |
|
Rituximab not be beneficial long-term in Sjorgen’s Syndrome
2 Minute Medicine 1. The results of this study suggest that rituximab (Rituxin) treatment is not associated with a significant improvement in symptoms or disease activity at 6 months for patients with primary Sjogren syndrome (pSS). 2. There were transient improvements … |
Annals of Internal Medicine tip sheet for Feb. 18, 2014Science CodexRituximab is an anti-CD20 antibody. Researchers conducted a multicenter, double-blind, placebo-controlled, randomized trial to evaluate the efficacy and harms of rituximab in adults wi…
|
Relief from Sjögren’s? Not With This Arthritis Rx
dailyRx The researchers concluded that rituximab was not tied to significant improvements in symptoms of primary Sjögren’s syndrome after 24 weeks. However, the medication did lead to improvements at week six, suggesting that it may have short-term … |
|
APS: More than Just a Thrombophilia
Pharmacy Times Some nonanticoagulant treatment options include the use of HMG Co-A reductase inhibitors (ie, “statins”) and rituximab. Statins potentially have a role in treating APS due to their anti-inflammatory, anticoagulant, and immunoregulatory effects … |
Research and Markets: Competitor Analysis: CD20 Antibodies – Rituximab …Fort Mills TimesThe present Competitive Intelligence Report about CD20 Antibodies – Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the fiel…
Research and Markets: Competitor Analysis: CD20 Antibodies – Rituximab …The Herald | HeraldOnline.com (press release)The present Competitive Intelligence Report about CD20 Antibodies – Rituximab Biosimilars and Biobetters/Biosuperiors provides a comp…
Research and Markets: Competitor Analysis: CD20 Antibodies – Rituximab …Business Wire (press release)The present Competitive Intelligence Report about CD20 Antibodies – Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluatio…